Opus Genetics (IRD) director Adrienne Graves awarded 24,367 restricted stock units

Rhea-AI Filing Summary

Graves Adrienne L reported acquisition or exercise transactions in this Form 4 filing.

Opus Genetics, Inc. director Adrienne L. Graves received a grant of 24,367 shares of Common Stock in the form of restricted stock units as compensation. These units vest upon the earlier of one year from the grant date or the day before the company’s next annual stockholder meeting, subject to continued service. After this award, Graves directly holds 127,514 shares of common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Graves Adrienne L

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	24,367	$0.00	--

Holdings After Transaction: Common Stock — 127,514 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 24,367 shares Grant price: $0.00 per share Post-transaction holdings: 127,514 shares +1 more

4 metrics

RSU grant size 24,367 shares Restricted stock units granted to director on acquisition-coded transaction

Grant price $0.00 per share Reported transaction price for RSU award

Post-transaction holdings 127,514 shares Total Common Stock directly held after the grant

Vesting condition Earlier of 1 year or pre–next annual meeting RSUs vest based on time and next stockholder meeting, with continued service

Key Terms

restricted stock units, annual meeting of stockholders, vesting date, grant, award, or other acquisition

4 terms

restricted stock units financial

"Represents a grant of restricted stock units which vest upon the earlier"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

annual meeting of stockholders financial

"the day prior to the Issuer's next annual meeting of stockholders occurring"

vesting date financial

"subject to the Reporting Person's continuing service through the vesting date"

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Graves Adrienne L

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/20/2026		A		24,367(1)	A	$0	127,514	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.

	/s/ Amy Rabourn, by Power of Attorney	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Opus Genetics (IRD) report for Adrienne L. Graves?

Opus Genetics reported that director Adrienne L. Graves received a grant of 24,367 restricted stock units of Common Stock. The award was recorded at a price of $0.00 per share, indicating a compensation-related equity grant rather than a market purchase.

How many Opus Genetics (IRD) shares does Adrienne L. Graves hold after this Form 4?

Following the grant, Adrienne L. Graves directly holds 127,514 shares of Opus Genetics Common Stock. This total includes the 24,367 restricted stock units reported in the filing, reflecting her overall direct equity position after the transaction.

How do the restricted stock units for Adrienne L. Graves at Opus Genetics vest?

The 24,367 restricted stock units granted to Adrienne L. Graves vest on the earlier of the one-year anniversary of the grant date or the day before Opus Genetics’ next annual meeting of stockholders, provided she continues in service through the vesting date.

Is the Form 4 transaction for Opus Genetics (IRD) a market buy or sale?

The Form 4 shows a grant or award acquisition, not an open-market buy or sale. The transaction is coded as “A” and priced at $0.00 per share, indicating equity compensation rather than a discretionary purchase or sale in the market.

What does transaction code “A” mean in the Opus Genetics (IRD) Form 4?

Transaction code “A” on the Form 4 represents a grant, award, or other acquisition of securities. In this case, it reflects the issuance of 24,367 restricted stock units of Opus Genetics Common Stock to director Adrienne L. Graves as part of her compensation.